Rivaroxaban, is factor Xa inhibitor, has been approved to decrease the risk of stroke and systemic embolism in NVAF at a dose of 20 mg orally once daily in patients with a creatinine clearance (CrCl) >50 mL/min, and a dose of 15 mg orally once daily in patients with a CrCl ≤ 50 mL/min. The gene discussed is F10; the disease is stroke disorder.